Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas. Al-Maghrabi, J., A., Butt, N., S., Anfinan, N., Sait, K., Sait, H., Marzouki, A., & Khabaz, M., N. Applied Immunohistochemistry & Molecular Morphology, 25(9):1, 2016. Paper Website doi abstract bibtex Introduction: Many studies described napsin A as a specific diagnostic marker that aids in differentiating lung adenocarcinomas from other respiratory tumors. This study describes the expression phenotype of napsin A in endometrial neoplasms, it investigates the relationship between this expression profile and the clinicopathologic parameters, and assess its utilization as an independent predictive marker. Methods: A total of 76 cases of previously diagnosed endometrial carcinoma (including 53 endometrioid adenocarcinomas, 6 endometrioid adenocarcinomas with squamous differentiation, 9 serous adenocarcinomas, 6 clear cell adenocarcinomas, and 2 malignant mixed mullerian tumors) and 30 tissue samples of noncancerous endometrium (including 16 proliferative endometriums, 10 secretory endometriums and 4 endometrial polyps) were retrieved from the archives of Pathology Department at King Abdulaziz University, Jeddah, Saudi Arabia. For napsin A detection, tissue microarrays and immunostaining were used. Results: A total number of 12 (15.78%) cases were positive for napsin A immunostaining. Brown granular cytoplasmic expression of napsin A was detected in 9.4% of endometrioid adenocarcinomas, 16.7% of endometrioid adenocarcinomas with squamous differentiation, 22.2% of papillary serous endometrial carcinomas, and 66.7% of clear cell carcinomas. Three (10%) control cases showed similar granular cytoplasmic expression. Positive napsin A immunostaining was more frequent in clear cell carcinoma, and there is a significant association between positive napsin A immunostaining and clear cell carcinoma (P-value=0.007). Significant associations have been found also between napsin A expression and older ages (above 60 y) and higher stage (IVB), the P-values of which were 0.035 and 0.043, respectively, but not with the tumor recurrence or survival rate. Conclusions: Although napsin A is infrequently expressed in endometrial carcinomas, positive results of napsin A immunostaining in endometrial neoplasms might support the diagnosis of clear cell carcinoma when the pathologic differential diagnosis includes other histologic subtypes.
@article{
title = {Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas},
type = {article},
year = {2016},
keywords = {clear cell carcinoma,endometrial endometrioid adenocarcinoma,immunohistochemistry,napsin A},
pages = {1},
volume = {25},
websites = {http://www.ncbi.nlm.nih.gov/pubmed/26945446%5Cnhttp://Insights.ovid.com/crossref?an=00129039-900000000-99117},
id = {1e3b6f00-e0f6-3f18-87db-fc4fe17dd89b},
created = {2021-08-31T15:29:47.194Z},
file_attached = {true},
profile_id = {49efd9d1-b84a-3562-b8db-36e64ac7ba81},
last_modified = {2021-08-31T15:47:31.396Z},
read = {false},
starred = {false},
authored = {true},
confirmed = {true},
hidden = {false},
citation_key = {Al-Maghrabi2016},
source_type = {JOUR},
folder_uuids = {4cfcf1ef-e8a1-481b-9768-92f271f79e14,5ddc3a8d-55b4-43f0-b1b2-dbebf8b6daac,61cd76d5-8771-4789-bd8b-c373e7bef009},
private_publication = {false},
abstract = {Introduction: Many studies described napsin A as a specific diagnostic marker that aids in differentiating lung adenocarcinomas from other respiratory tumors. This study describes the expression phenotype of napsin A in endometrial neoplasms, it investigates the relationship between this expression profile and the clinicopathologic parameters, and assess its utilization as an independent predictive marker. Methods: A total of 76 cases of previously diagnosed endometrial carcinoma (including 53 endometrioid adenocarcinomas, 6 endometrioid adenocarcinomas with squamous differentiation, 9 serous adenocarcinomas, 6 clear cell adenocarcinomas, and 2 malignant mixed mullerian tumors) and 30 tissue samples of noncancerous endometrium (including 16 proliferative endometriums, 10 secretory endometriums and 4 endometrial polyps) were retrieved from the archives of Pathology Department at King Abdulaziz University, Jeddah, Saudi Arabia. For napsin A detection, tissue microarrays and immunostaining were used. Results: A total number of 12 (15.78%) cases were positive for napsin A immunostaining. Brown granular cytoplasmic expression of napsin A was detected in 9.4% of endometrioid adenocarcinomas, 16.7% of endometrioid adenocarcinomas with squamous differentiation, 22.2% of papillary serous endometrial carcinomas, and 66.7% of clear cell carcinomas. Three (10%) control cases showed similar granular cytoplasmic expression. Positive napsin A immunostaining was more frequent in clear cell carcinoma, and there is a significant association between positive napsin A immunostaining and clear cell carcinoma (P-value=0.007). Significant associations have been found also between napsin A expression and older ages (above 60 y) and higher stage (IVB), the P-values of which were 0.035 and 0.043, respectively, but not with the tumor recurrence or survival rate. Conclusions: Although napsin A is infrequently expressed in endometrial carcinomas, positive results of napsin A immunostaining in endometrial neoplasms might support the diagnosis of clear cell carcinoma when the pathologic differential diagnosis includes other histologic subtypes.},
bibtype = {article},
author = {Al-Maghrabi, Jaudah A. and Butt, Nadeem S. and Anfinan, Nisrin and Sait, Khalid and Sait, Hesham and Marzouki, Anas and Khabaz, Mohamad Nidal},
doi = {10.1097/PAI.0000000000000350},
journal = {Applied Immunohistochemistry & Molecular Morphology},
number = {9}
}
Downloads: 0
{"_id":"F4hmMfkd2PpeMbbXa","bibbaseid":"almaghrabi-butt-anfinan-sait-sait-marzouki-khabaz-infrequentimmunohistochemicalexpressionofnapsinainendometrialcarcinomas-2016","author_short":["Al-Maghrabi, J., A.","Butt, N., S.","Anfinan, N.","Sait, K.","Sait, H.","Marzouki, A.","Khabaz, M., N."],"bibdata":{"title":"Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas","type":"article","year":"2016","keywords":"clear cell carcinoma,endometrial endometrioid adenocarcinoma,immunohistochemistry,napsin A","pages":"1","volume":"25","websites":"http://www.ncbi.nlm.nih.gov/pubmed/26945446%5Cnhttp://Insights.ovid.com/crossref?an=00129039-900000000-99117","id":"1e3b6f00-e0f6-3f18-87db-fc4fe17dd89b","created":"2021-08-31T15:29:47.194Z","file_attached":"true","profile_id":"49efd9d1-b84a-3562-b8db-36e64ac7ba81","last_modified":"2021-08-31T15:47:31.396Z","read":false,"starred":false,"authored":"true","confirmed":"true","hidden":false,"citation_key":"Al-Maghrabi2016","source_type":"JOUR","folder_uuids":"4cfcf1ef-e8a1-481b-9768-92f271f79e14,5ddc3a8d-55b4-43f0-b1b2-dbebf8b6daac,61cd76d5-8771-4789-bd8b-c373e7bef009","private_publication":false,"abstract":"Introduction: Many studies described napsin A as a specific diagnostic marker that aids in differentiating lung adenocarcinomas from other respiratory tumors. This study describes the expression phenotype of napsin A in endometrial neoplasms, it investigates the relationship between this expression profile and the clinicopathologic parameters, and assess its utilization as an independent predictive marker. Methods: A total of 76 cases of previously diagnosed endometrial carcinoma (including 53 endometrioid adenocarcinomas, 6 endometrioid adenocarcinomas with squamous differentiation, 9 serous adenocarcinomas, 6 clear cell adenocarcinomas, and 2 malignant mixed mullerian tumors) and 30 tissue samples of noncancerous endometrium (including 16 proliferative endometriums, 10 secretory endometriums and 4 endometrial polyps) were retrieved from the archives of Pathology Department at King Abdulaziz University, Jeddah, Saudi Arabia. For napsin A detection, tissue microarrays and immunostaining were used. Results: A total number of 12 (15.78%) cases were positive for napsin A immunostaining. Brown granular cytoplasmic expression of napsin A was detected in 9.4% of endometrioid adenocarcinomas, 16.7% of endometrioid adenocarcinomas with squamous differentiation, 22.2% of papillary serous endometrial carcinomas, and 66.7% of clear cell carcinomas. Three (10%) control cases showed similar granular cytoplasmic expression. Positive napsin A immunostaining was more frequent in clear cell carcinoma, and there is a significant association between positive napsin A immunostaining and clear cell carcinoma (P-value=0.007). Significant associations have been found also between napsin A expression and older ages (above 60 y) and higher stage (IVB), the P-values of which were 0.035 and 0.043, respectively, but not with the tumor recurrence or survival rate. Conclusions: Although napsin A is infrequently expressed in endometrial carcinomas, positive results of napsin A immunostaining in endometrial neoplasms might support the diagnosis of clear cell carcinoma when the pathologic differential diagnosis includes other histologic subtypes.","bibtype":"article","author":"Al-Maghrabi, Jaudah A. and Butt, Nadeem S. and Anfinan, Nisrin and Sait, Khalid and Sait, Hesham and Marzouki, Anas and Khabaz, Mohamad Nidal","doi":"10.1097/PAI.0000000000000350","journal":"Applied Immunohistochemistry & Molecular Morphology","number":"9","bibtex":"@article{\n title = {Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas},\n type = {article},\n year = {2016},\n keywords = {clear cell carcinoma,endometrial endometrioid adenocarcinoma,immunohistochemistry,napsin A},\n pages = {1},\n volume = {25},\n websites = {http://www.ncbi.nlm.nih.gov/pubmed/26945446%5Cnhttp://Insights.ovid.com/crossref?an=00129039-900000000-99117},\n id = {1e3b6f00-e0f6-3f18-87db-fc4fe17dd89b},\n created = {2021-08-31T15:29:47.194Z},\n file_attached = {true},\n profile_id = {49efd9d1-b84a-3562-b8db-36e64ac7ba81},\n last_modified = {2021-08-31T15:47:31.396Z},\n read = {false},\n starred = {false},\n authored = {true},\n confirmed = {true},\n hidden = {false},\n citation_key = {Al-Maghrabi2016},\n source_type = {JOUR},\n folder_uuids = {4cfcf1ef-e8a1-481b-9768-92f271f79e14,5ddc3a8d-55b4-43f0-b1b2-dbebf8b6daac,61cd76d5-8771-4789-bd8b-c373e7bef009},\n private_publication = {false},\n abstract = {Introduction: Many studies described napsin A as a specific diagnostic marker that aids in differentiating lung adenocarcinomas from other respiratory tumors. This study describes the expression phenotype of napsin A in endometrial neoplasms, it investigates the relationship between this expression profile and the clinicopathologic parameters, and assess its utilization as an independent predictive marker. Methods: A total of 76 cases of previously diagnosed endometrial carcinoma (including 53 endometrioid adenocarcinomas, 6 endometrioid adenocarcinomas with squamous differentiation, 9 serous adenocarcinomas, 6 clear cell adenocarcinomas, and 2 malignant mixed mullerian tumors) and 30 tissue samples of noncancerous endometrium (including 16 proliferative endometriums, 10 secretory endometriums and 4 endometrial polyps) were retrieved from the archives of Pathology Department at King Abdulaziz University, Jeddah, Saudi Arabia. For napsin A detection, tissue microarrays and immunostaining were used. Results: A total number of 12 (15.78%) cases were positive for napsin A immunostaining. Brown granular cytoplasmic expression of napsin A was detected in 9.4% of endometrioid adenocarcinomas, 16.7% of endometrioid adenocarcinomas with squamous differentiation, 22.2% of papillary serous endometrial carcinomas, and 66.7% of clear cell carcinomas. Three (10%) control cases showed similar granular cytoplasmic expression. Positive napsin A immunostaining was more frequent in clear cell carcinoma, and there is a significant association between positive napsin A immunostaining and clear cell carcinoma (P-value=0.007). Significant associations have been found also between napsin A expression and older ages (above 60 y) and higher stage (IVB), the P-values of which were 0.035 and 0.043, respectively, but not with the tumor recurrence or survival rate. Conclusions: Although napsin A is infrequently expressed in endometrial carcinomas, positive results of napsin A immunostaining in endometrial neoplasms might support the diagnosis of clear cell carcinoma when the pathologic differential diagnosis includes other histologic subtypes.},\n bibtype = {article},\n author = {Al-Maghrabi, Jaudah A. and Butt, Nadeem S. and Anfinan, Nisrin and Sait, Khalid and Sait, Hesham and Marzouki, Anas and Khabaz, Mohamad Nidal},\n doi = {10.1097/PAI.0000000000000350},\n journal = {Applied Immunohistochemistry & Molecular Morphology},\n number = {9}\n}","author_short":["Al-Maghrabi, J., A.","Butt, N., S.","Anfinan, N.","Sait, K.","Sait, H.","Marzouki, A.","Khabaz, M., N."],"urls":{"Paper":"https://bibbase.org/service/mendeley/49efd9d1-b84a-3562-b8db-36e64ac7ba81/file/66a77d10-9015-a7c1-6df9-1ba4a927697b/Al_Maghrabi_et_al___2016___Infrequent_Immunohistochemical_Expression_of_Napsin_A_in_Endometrial_Carcinomas.pdf.pdf","Website":"http://www.ncbi.nlm.nih.gov/pubmed/26945446%5Cnhttp://Insights.ovid.com/crossref?an=00129039-900000000-99117"},"biburl":"https://bibbase.org/service/mendeley/49efd9d1-b84a-3562-b8db-36e64ac7ba81","bibbaseid":"almaghrabi-butt-anfinan-sait-sait-marzouki-khabaz-infrequentimmunohistochemicalexpressionofnapsinainendometrialcarcinomas-2016","role":"author","keyword":["clear cell carcinoma","endometrial endometrioid adenocarcinoma","immunohistochemistry","napsin A"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/service/mendeley/49efd9d1-b84a-3562-b8db-36e64ac7ba81","dataSources":["JnyAdS67Rhkx3LrTM"],"keywords":["clear cell carcinoma","endometrial endometrioid adenocarcinoma","immunohistochemistry","napsin a"],"search_terms":["infrequent","immunohistochemical","expression","napsin","endometrial","carcinomas","al-maghrabi","butt","anfinan","sait","sait","marzouki","khabaz"],"title":"Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas","year":2016}